Natural Killer Cell Therapy Articles & Analysis
23 news found
In the rapidly evolving landscape of pharmaceutical innovations, CD Formulation emerges as a key player, offering customized drug conjugates services that cater to the rising demands for advanced drug development. Specializing in complex biologic formulations, Biologics & Biosimilars service team of CD Formulation is revolutionizing how drug conjugate products are conceptualized and produced, ...
CAR-T (chimeric antigen receptor T-cell) and CAR-NK (chimeric antigen receptor natural killer cell) therapies involve genetically modifying a patient's own immune cells to recognize and attack cancer cells more efficiently. ...
Exclusive global license for CORE NK platform (CHM 0201) executed with Case Western Reserve University in Ohio Initial Phase 1 clinical trial results of the CORE NK platform (CHM 0201) were published demonstrating safety and encouraging activity in blood cancers and solid tumours One patient achieved a complete response that was sustained for over 15 months at time of publication Based on ...
AFM28 binds to natural killer (NK) cells and CD123-positive tumor cells and demonstrated the induction of tumor cell killing in vitro and a good tolerability and strong anti-tumor activity in vivo. ...
Senti Bio's oncology pipeline uses healthy adult donor-derived, natural killer (NK) cells engineered with chimeric antigen receptor (CAR) gene circuits that are cryopreserved and dosed off-the-shelf. Senti Bio’s oncology pipeline is primarily focused on three preclinical-stage programs: SENTI-202, a Logic Gated (OR+NOT) off-the-shelf CAR-NK ...
Yago Nieto, M.D., Ph.D., Professor of Stem Cell Transplantation and Cellular Therapy at MD Anderson, presented follow-up data to the investigator sponsored trial (IST) (AFM13-104) investigating the combination of AFM13 pre-complexed with cord blood-derived natural killer cells followed by AFM13 monotherapy in ...
Senti Bio's oncology pipeline uses healthy adult donor-derived, natural killer (NK) cells engineered with chimeric antigen receptor (CAR) gene circuits that are cryopreserved and dosed off-the-shelf. ...
(CytoImmune), a clinical-stage immunotherapy company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies. G-CON PODs were built in College Station and have been shipped and integrated into CytoImmune’s custom-designed facility. ...
The presentations highlight new data related to the application of gene circuit technology to enhance efficacy and safety of cancer-killing allogeneic chimeric antigen receptor (CAR) natural killer (NK) cells. “This year's ASGCT presentations mark significant progress across our pipeline of allogeneic gene circuit-enabled CAR-NK ...
Ongoing Phase 1 study of unmodified placental-derived natural killer (NK) cell therapy candidate, CYNK-001, in acute myeloid leukemia (AML) continues enrolling new cohorts to reflect adjustments to treatment regimen and dosing as outlined in December 2021 Ongoing Phase 1 study of CYNK-001 in glioblastoma multiforme ...
Correlative science data from AFM24-101 clinical study support the rationale to develop AFM24 as monotherapy and in combination therapies First preclinical data set on the combination of AFM28 with natural killer cells, both in co-administration or pre-complexed, demonstrates cytotoxic activity against CD123-positive tumor ...
Logic Gated FLT3 OR CD33 NOT EMCN CAR-NK Cell Therapy (SENTI-202) for Precise Targeting of AML, Garrison et al. ...
CB-011 is an allogeneic anti-BCMA CAR-T cell therapy immune cloaked to blunt both T- and NK-mediated immune cell rejection, enabling more durable antitumor activity -- Data support an expected Investigational New Drug (IND) application submission in 2022 for CB-011, Caribou’s second allogeneic cell ...
Two ongoing Phase 1 trials of unmodified placental-derived natural killer cell therapy candidate, CYNK-001, in acute myeloid leukemia (AML) and glioblastoma multiforme (GBM) An ongoing Phase 1 portion of a Phase 1/2a trial of genetically modified placental-derived natural killer ...
(Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational natural killer (NK) cell therapy, ...
(Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived ...
Poster no. 2773: “Human Placental CD34+-Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 (CYNK-101) in Combination with Daratumumab for Immunotherapy Against CD38 Expressing Hematological Malignancies” Session name: 703. ...
FT516 is the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, which is designed to maximize antibody-dependent cellular cytotoxicity (ADCC), a ...
-SITC 2021, re-hosted face to face meeting for the first time in 2 years due to COVID-19…topic for overcoming tolerance of Immuno-oncology -International researchers pay attention to immuno-oncology GI-101’s material excellence that had the mechanism of overcoming tolerance GI Innovation revealed KEYNOTE-B59’s clinical research process of GI-101(CD80/IL-2 variant bispecific ...
Thermo Fisher Scientific today announced the launch of Gibco Cell Therapy Systems (CTS) NK-Xpander Medium, a GMP-manufactured cell culture medium that supports large-scale growth and culture of functional natural killer (NK) cells with or without the use of feeder cells. ...